Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EYA3 | Q99504 | 6/20 | 1.00 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.82 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TTR | P02766 | 2/20 | 0.69 |
| ▸ | PGR | P06401 | 2/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | DRD1 | P21728 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzarone SCHEMBL29576057 | 1.00 | EYA3 (1.00) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 | |
| Benzarone SCHEMBL28587332 | 0.99 | EYA3 (0.97) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 | |
| SCHEMBL1287913 | 0.89 | EYA3 (0.81) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 | |
| SCHEMBL11840583 | 0.89 | EYA3 (0.85) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 | |
| SCHEMBL12286119 | 0.88 | EYA3 (0.79) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 | |
| SCHEMBL28101771 | 0.88 | EYA3 (0.79) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 | |
| SCHEMBL27935343 | 0.88 | EYA3 (0.77) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 | |
| SCHEMBL1287385 | 0.87 | EYA3 (0.77) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 | |
| SCHEMBL1287970 | 0.86 | EYA3 (1.00) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 | |
| SCHEMBL1287413 | 0.85 | SLC22A12 (1.00) | EYA3SLC22A12CYP2C9PTPN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250009655-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC | 2025-01-09 | — | — | US | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| WO-2023225282-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1998027899-A1 | PROPHYLACTIC SYSTEM WITH VASODILATOR-CONTAINING FILM | BENDIS INA K (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0366156-B1 | Composition for the treatment of diseases of the veins and the anal region | ROSHDY ISMAIL (DE) | 1995-01-11 | — | — | EP | claimed |
| US-4230702-A | Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents | KALI-CHEMIE PHARMA GMBH (DE) | 1980-10-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | EYA3 1388/4885SLC22A12 395/4885CYP2C9 4501/4885 |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | EYA3 4051/4885SLC22A12 4783/4885CYP2C9 2996/4885 |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | EYA3 1314/4885SLC22A12 2053/4885CYP2C9 47/4885 |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | EYA3 1314/4885SLC22A12 2053/4885CYP2C9 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.